Neuroplast BV is an independent company founded in 2013 and embedded in the Science Society of Brightlands Maastricht (www.brightlands.com), Netherlands. The company is founded and driven by professionals able to translate basic science in concrete strategies, and to commercialize these concepts to the market. Transparency by sharing their experimental developments, results and ideas with the world-wide medical community is considered essential to reach these goals. Neuroplast’s starting point is to develop therapeutic strategies interfering with the various processes leading to neurodegeneration by reducing inflammation and increasing neuroplasticity (neuroprotection, neurorepair), an unmet need in many idiopathic, traumatic and ischemic neurodegenerative disorders.
Neuroplast is an independent company, 100% owned by Neuroplast Beheer BV. Neuroplast Beheer BV only helds the intellectual property, Neuroplast BV employs the faculty, a small ‘clean and lean’ staff, flexible enough to adapt to today’s challenges in personalized health care in an industrialized way, with a broad experience in managing start-up companies; dealing with regulatory issues including the development of orphan-designations and medical need programs; and developing translational cell based therapies, using the patient own . In concordance with her ‘translational’ mission, Neuroplast is located in the University Maastricht-affiliated Maastricht Health Campus, and has an extensive national and international academic and commercial network.
Neuroplast is (co)founded by two physicians with a comprehensive experience in the treatment of neurodegenerative disorders including spinal cord injuries, parkinsonism and dementia, and dealing with (inter)national regulations concerning ATMPs or biomaterials. They are both experts driven by translational science and the enthusiasm to change the outcome of patients suffering these debilitating neurodegenerative disorders. Realizing that, as of yet, cure for these disorders is not possible, the goals of the team of Neuroplast to achieve in these patients mainly comprise to prolong their life with an improved quality of life and independency.
Scientific Advisory Board Neuroplast has an international advisory board of world-wide key opinion leaders in the field of neurodegeneration and cell-based technology.
Neuroplast BV is a company initially funded by their owners. In 2015 the Ministery of Economics (Rijksdienst voor Ondernemend Nederland) provided Neuroplast BV with an innovation credit to cover the expenses for their proof of concept study performed by the University of Maastricht. In the third quarter of 2015 Neuroplast BV was also able to obtain an European Grant for the development of a CE certified platform, AMARYLLIS. As of now, Neuroplast BV is still interested in dilutive and non-dilutive funding to enable the execution of their development plan to bring their first product NEUROCELL to the European as well the United States market. Investors interested to contribute to the successes of Neuroplast BV are invited to contact the management to discuss mutual opportunities.
In case you are a master student looking for an exciting internship, or if are you interested to participate into a PhD trajectory? Neuroplast, firmly embedded in the University of Maastricht (Department of Mental Health and Neuroscience) offers exciting opportunities, ranging from biochemical research to business development. Whatever your starting point, we will inspire and motivate you to reach your goals. Internships have a minimum duration of six months, and are structured to provide proper training with active participation in our actual programs and/or the development of our next projects. To apply for an internship at Neuroplast, please contact our staff. We look forward to discuss your expertise and interests as the potential start of a rewarding internship!
Neuroplast is a dynamic company with challenging projects and a highly committed and talented staff. Our company offers the opportunity for intellectual development, preclinical and clinical scientific experience, multidisciplinary cooperation and strategic planning. We are looking for you if you have a background in (analytical) pharmaceutical or medical biology, with experience in industrial pharmaceutical product development. Please approach our managing team and learn about our actual positions and possible future openings.
Prof. Erik Ch. Wolters is a neurologist, certified by the Dutch as well as Swiss Association of Neurology, who served initially (since 1978) at the University of Amsterdam (AMC) and later (from 1984) at the VU University Medical Centre in Amsterdam (The Netherlands). In 1986 he worked during a year at the Dept. of Neurology at the University of British Columbia in Vancouver (Canada) where he got a special training in basic neuroscience. Subsequently, he was directing a clinic for Movement Disorders at the VU-UMC where he was appointed full professor in 2000. Since his retirement in 2010, he acts as a consultant for the Department of Neurology of the University of Zurich (Switzerland), and joined Amarna Therapeutics in Leiden (The Netherlands) where he plunged into stem cell research and genetic engineering. In 2015 he co-founded Neuroplast in Maastricht (The Netherlands) in order to develop new therapeutic cell-based strategies for neurodegenerative disorders, in close cooperation with the University of Maastricht. Prof. Wolters wrote about 300 peer reviewed medical articles, mainly dealing with neurodegenerative disorders, as well as many book chapters, and various textbooks on Neurology and Movement Disorders. In 2007 and again in 2011, Dr. Wolters was elected as president of the Research Group of the World Federation of Neurology on Parkinsonism and Related Disorders (the actual International Association of Parkinsonism and Related Disorders). In 2015 he was awarded with the honorary membership of this Association and joined the board as past-president. He is also honorary member of the European Society of Clinical Neuropharmacology (ESCPN), the Pakistan Society of Neurology and the Dutch Parkinson’s Disease Association, and senior member of the American Neurological Association. Recently, by resolution of Academic Council of Tashkent Medical Academy, prof. Wolters was given a honorary professorship of the Tashkent Medical Academy. Dr. Wolters received various international awards, among them the gold medal of the Italian Society of Neurology (1982), the Charles E. Smith Award (2008), the Hans Lakke Award (2010) and the Senator Burda Award (2011).
Johannes P.J.M. de Munter has a medical background, he is a registered epidemiologist and has been active in medical sciences for more than 32 years. He started as emergency health care physician, general practitioner and specialist infectious diseases, and worked for 15 years as deputy director at the Municipal Department of Public Health and Infectious Disease Control in the southern part of the Netherlands. The last 10 years he was especially involved in Research and development within Medtronic Vitatron (implantable monitor devices) and within German stem cell clinics (autologous stem cell treatments). He has an extended experience in start-up management of small medical companies, and has expertise in regulatory affairs and translational research development. So, he was able to arrange for European approval of two multicenter clinical trials with autologous stem cells. Dr de Munter is (co)author of 8 peer reviewed articles. He is one of the co-founders of Neuroplast BV in January 2013 and is responsible to develop an autologous stem cell based product for the treatment of various neurodegenerative disorders, including spinal cord injury, parkinsonism and multiple sclerosis, and to bring those products to the market. Since 2014, Dr de Munter is also employed at the University Maastricht, Department Mental Health and Neuroscience.
Raf M.J. Donders is Senior Scientist of product development at the Research and Development division of Neuroplast BV. His research is focused on the development and production of low immunogenic and immune modulatory cell products derived from bone marrow. He focuses on immunological and regenerative mechanisms of these cells, that limit immune mediated damage to the central nervous system. His previous work experience involved the preclinical investigation of umbilical cord matrix derived stem cells in the context of cell-based therapy for multiple sclerosis (MS). He performed his PhD research at the Biomedical Research Institute of Hasselt University. ‘He is currently in the progress of finalizing his thesis and will defend in spring of 2016.’ His work focused on the assessment of the immunological and regenerative properties of human Wharton’s jelly derived stem cells in vitro and in an animal model of MS. During his research, a wide variety of functional assays were applied including microarray analysis (comparing to bone marrow MSC), stem cell phenotype assessment (differentiation, marker expression analysis, in situ label-free microscopy, electron microscopy), functional in vitro assays (suppression co-cultures with PBMC and DC, cytokines analysis), and multicolor flow cytometric phenotyping. Apart from the in vitro research, transplantation studies in the experimental animal models for MS (EAE) were performed. Donders has published 2 international peer-reviewed papers and has currently submitted 2 manuscripts for publication. His work was funded by a personal SBO-IWT grant and Hasselt University.
Jana van Gerwen is a master of science, medical engineer, specialized in medical engineering, biomechanics and tissue engineering. She is holder of the Lean Sigma, Black Belt. Jana is working for Neuroplast as a translational scientist mainly focusing on quality assurance and helping to develop the manufacturing of stem cell products in a diligent and efficient way, implanting the Lean Sigma methodology right from the start. As of yet, she is combining these activities with her work as product and process specialist for Holland Innovative, located in Eindhoven, focusing on Teledyne DALSA and Philips handheld diagnostics. In the past she was working with Pie Medical Imaging BV as sales engineer and later on product development engineer.
Leo L. W. Janssen is an experienced, enthousiastic biological technician, acxtive in the field of cellular medicine, who joined Neuroplast after working as a research technician in the department of Pediatrics, Maastricht University from 2011 – 2016. After graduation in the Fontys Hogeschool Eindhoven in 2011 (with specialization in Life Sciences: epidemiology, medical microbiology, immunology, genetics, Genomics & Proteomics), in this department, he was working in a multidisciplinary environment, with full responsibility for general laboratory tasks. During those years, he developed, executed and reported experiments, analysing and interpreting the results. He also developed and supervised practical and educational teaching programs for students and colleagues, and chaired discussion programs regarding eventual improvements, innovative laboratory techniques and new equipments. Leo is familiar with molecular (DNA/RNA isolation, PCR, Real-time PCR) and histological techniques, immunohistochemistry and fluorescent immunohistochemistry, ELISA, Western Blot and cell culture techniques.
6229 EV Maastricht